Date Title View
Oct 16, 2009
Jan 29, 2010
Jun 19, 2012
Dec 4, 2012
Dec 17, 2012
Jan 4, 2013
Apr 18, 2013
WOBURN, Mass., April 18, 2013 -  Flexion Therapeutics, Inc. announced today the presentation of a poster titled "FX006 prolongs the residency of triamcinolone acetonide in the synovial tissues of patients with knee osteoarthritis" at Osteoarthritis Research Society International's (OARSI) 20...
May 20, 2013
WOBURN, Mass., May 20, 2013 -  Flexion Therapeutics, Inc. today announced the addition of Frederick W. Driscoll to its management team as chief financial officer. Mr. Driscoll has more than 30 years of financial management experience with biotechnology and medical device companies. P...
Jun 26, 2013
BURLINGTON, Mass., June 26, 2013 - Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular (IA), sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release s...
Oct 2, 2013
BURLINGTON, MASS., OCTOBER 2, 2013 - Flexion Therapeutics, Inc. announced today that new data from a Phase 2b dose-ranging trial of the company's lead compound, FX006, in osteoarthritis (OA) has been accepted for an oral presentation at the 2013 Annual Scientific Meeting of the American Co...
... NextLast
= add release to Briefcase